A Study in Male and Female Adolescent Participants With Severe Uncontrolled Asthma Starting Treatment With Dupilumab Injection (Dupixent®)
Study Overview
Primary objective:
- Describe the characteristics of enrolled severe asthma patients
Secondary objectives:
- Assess the control of asthma under dupilumab (Dupixent®) treatment until 1 year
- Assess the clinical objectives of the asthma care
- Assess comorbidities associated with Type 2 inflammation
- Assess safety during the year of treatment
Study details
52 weeks
Eligibility Criteria
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Asthma
-
Age: Between 12 Years - 17 Years
-
Gender: All
Inclusion Criteria:
- Adolescents, for whom initiation of dupilumab (Dupixent®) for the severe uncontrolled asthma indication was decided by the investigator before the inclusion in the study
- Adolescents ≥ 12 and < 18 years of age at the time of the initiation of Dupixent® treatment
Exclusion Criteria:
- Adult participants ≥ 18 years of age
The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
Updated on
27 Mar 2024.
Study ID: NCT05070663
Find a Study Location to Connect
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact